Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion.

Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period. Pfizer's dismal stock performance in recent years underscores the challenges the big drugmaker faces.

Pfizer no longer has any SCD treatments on the market after voluntarily stopping Oxbryta sales last fall, citing clinical information that “now indicates the overall benefit of Oxbryta no longer ...

Pick a time frame -- year to date, last 12 months, last three years, last five years, or last 10 years. Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period.

Sickle Cell Disease Market Insight, Epidemiology And Market Forecast - 2034The sickle cell disease treatment market is experiencing signific ...

Pfizer has experienced disappointing product and pipeline setbacks as well. It withdrew sickle cell disease therapy Oxbryta from the market last year after concluding that the benefits no longer ...

The Sickle Cell Disease Treatment Market is expected to reach at a CAGR of 15.8% during the forecast period 2025-2033. The Sickle Cell Disease Treatment Market is growing due to rising disease ...

From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 7 ...

Pfizer (NYSE:PFE) stock is a biopharmaceutical firm that had a magnificent breakout in 2021 as the worst of the pandemic sent COVID vaccine demand through the roof. Since that peak, it’s been a ...